MedPath

Clinical Evaluation of the Treatment of Spider Angioma

Not Applicable
Completed
Conditions
Spider Angioma
Interventions
Device: KTP laser
Registration Number
NCT02755467
Lead Sponsor
Cutera Inc.
Brief Summary

To evaluate the safety and effectiveness of the laser treatment for the treatment of spider angiomas.

Detailed Description

The purpose of this study is to evaluate the safety and efficacy of the 532 nm KTP laser within the Cutera Excel V system for the treatment of spider angiomas.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  1. Males or females, 5 to 65 years of age (inclusive).
  2. Fitzpatrick Skin Types I-IV
  3. Subject must be able to read, understand and sign the Informed Consent Form.
  4. If subject is a minor (<18 years old in Illinois), Assent must be obtained from the subject and a Parental Consent Form must be signed by the parents or legal guardian.
  5. Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
  6. Willing to have limited sun exposure for the duration of the study, including the follow-up period.
  7. Willingness to have digital photographs taken of their spider angioma(s) and agree to use of photographs for presentation, educational or marketing purposes
  8. Agree not to undergo any other procedure for the treatment of spider angioma during the study.
Exclusion Criteria
  1. Pregnant.
  2. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
  3. Having a known anti-coagulative condition or taking anticoagulation medications, including aspirin.
  4. History of seizure disorders due to light.
  5. Systemic use of isotretinoin (Accutane®) within 6 months of study participation.
  6. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
  7. Participation in a study of another device or drug within 3 months prior to enrollment or during the study.
  8. In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systemic therapy that could interfere with this research study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Laser treatmentKTP laserEach subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
Primary Outcome Measures
NameTimeMethod
Physician's Global Assessment Scale for Improvement of Spider AngiomaFour weeks post laser treatment.

Assessment of Baseline vs. 4 weeks post-final treatment for improvement of spider angiomas using the Physician's Global Assessment scale.

High scores indicate better outcomes:

0. None

1. Mild

2. Moderate

3. Significant

4. Very Significant

5. Complete Removal

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

DuPage Medical Group

🇺🇸

Naperville, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath